Company: NEOG
Filing Date: 2025-09-12
Form Type: DEF 14A
Source: 0000950170-25-114381
Chunk: 12

Company: NEOGEN CORP
Filing Date: 2025-09-12
Form: DEF 14A
Chunk 12
---
| •Governance                             
 •Science, Technology and Innovation     
 •Digital, Healthcare, and AI Industries 
 •Innovation and Emerging Technology     
 •International                          
 •Executive Leadership                   |

| Neogen Corporation | 2025 Proxy Statement | 13 |

#### Proposal 1: Election of Directors
| Raphael A. Rodriguez                |     |                     |        |
|                                     |     | Director Since 2020 | Age 57 |
| •Compensation                       
 •Science, Technology and Innovation 
 •Digital and AI Industries          
 •Innovation and Emerging Technology 
 •Startups                           
 •Research and Development           
 •Executive Leadership               |     |                     |        |

| Dr. Catherine E. Woteki             |     |                     |        |
|                                     |     | Director Since 2020 | Age 77 |
| •Compensation                       
 •Science, Technology and Innovation 
 •Food and Agriculture Industries    
 •Regulatory                         
 •Research and Development           |     |                     |        |

| Neogen Corporation | 2025 Proxy Statement | 14 |

Proposal 2: To Approve, On An Advisory Basis, The Compensation of Named Executive Officers

Proposal 2: To Approve, On An Advisory Basis, The Compensation of Named Executive Officers

The “Compensation Discussion and Analysis” section of this Proxy Statement describes, among other things, the Company’s executive compensation policies and practices. Federal laws require that our shareholders be given the opportunity to provide, on an advisory basis, approval of the compensation of Company executives, as disclosed in this Proxy Statement and, therefore, we are providing this advisory proposal as required by Section 14A of the Exchange Act. Under the legislation that requires this vote, the shareholder vote is neither binding on the Board nor the Company and may not be construed as overruling any decision made by the Board or the Company or as creating or implying any change in the fiduciary duties owed by the Board. However, the Board values the views of shareholders and intends to take the outcome of this annual shareholder advisory vote into consideration when making future executive compensation decisions.

Therefore, at the Annual Meeting, shareholders will be given the opportunity to vote, on an advisory basis, to approve the compensation of the named executive officers as disclosed in this Proxy Statement under “Compensation Discussion and Analysis” and “Summary Compensation Table.” This vote proposal is commonly known as a “say-on-pay” proposal and gives shareholders the opportunity to endorse or not endorse the executive pay program. This vote is not intended to address any specific item of executive compensation